---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-068443"
form_type: "8-K"
ticker: "AZTA"
cik: "0000933974"
company_name: "Azenta, Inc."
filed_at: "2026-10-30T12:02:38+00:00"
generated_at: "2026-10-30T12:05:12.954925+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Azenta takes exclusive Elegen gene-synthesis license and buys SynPlexity to expand GENEWIZ

## Summary
- Exclusive, royalty-free license to Elegen's gene synthesis and cell-free cloning patents and know-how; initial five-year term, extendable by mutual agreement.
- Azenta can exercise an option 12-18 months after signing, paying $25M, to convert to an irrevocable, perpetual, exclusive, royalty-free license.
- Aggregate capital deployment of $32M-$71M, depending on future equipment purchases and whether Azenta exercises the perpetual-license option.
- Acquired all outstanding stock of SynPlexity Inc. under an Oct. 28, 2026 Stock Purchase Agreement that closed concurrently; purchase price not disclosed.
- SynPlexity's pooled gene assembly yields thousands of full-length gene variants per library; technology to be folded into the GENEWIZ synthesis portfolio.

## SEC filing metadata
- accession: 0001628280-26-068443
- form_type: 8-K
- ticker: AZTA
- cik: 0000933974
- company_name: Azenta, Inc.
- filed_at: 2026-10-30T12:02:38+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/933974/000162828026068443/0001628280-26-068443-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/933974/000162828026068443/azta-20261028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-068443
- JSON: https://secwatch.observer/filing/0001628280-26-068443.json
- Plain text: https://secwatch.observer/filing/0001628280-26-068443.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.